Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-04-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiapatients mustcellcancerpatient
  Phrases that lowered it: receiveddrugtrialdays beforeprimary
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.6% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 95.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 19.5% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 712 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT00955916 · started 2009 · scored riskier than 99% of active trials completed
• Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia NCT01222143 · started 2010 · scored riskier than 88% of active trials terminated
• Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia NCT01260714 · started 2010 · scored riskier than 58% of active trials terminated
• An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) NCT01498445 · started 2012 · scored riskier than 88% of active trials terminated
• Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia NCT00852566 · started 2009 · scored riskier than 54% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.